Sign In
12 Nov 2015 07:00
PRESS RELEASE
12 November 2015
SYNAIRGEN PLC
("Synairgen" or "the Company")
Directors' Share Purchase
Southampton, UK, 12 November 2015: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, was informed that on 11 November 2015 the following Directors acquired ordinary shares of 1p each in the Company ("Ordinary Shares") at a price of 23p per Ordinary Share as follows:
Interest before purchase | Interest after purchase | ||||
Director | Title | Number of Ordinary Shares | Number of Ordinary Shares acquired | Number of Ordinary Shares | % of total issued share capital |
Richard Marsden | CEO | 110,972 | 43,460 | 154,432 | 0.17% |
Dr Philip Monk | CSO | 161,710 | 21,729 | 183,439 | 0.20% |
John Ward | FD | 243,912 | 32,594 | 276,506 | 0.30% |
Simon Shaw (Note 1) | Chairman | 1,408,879 | 65,217 | 1,474,096 | 1.61% |
Note 1 Simon Shaw's shareholding includes 105,516 Ordinary Shares held in his pension plan.
ENDS
For further information, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, James Thompson (Corporate Finance)
Stephen Norcross, Simon Johnson (Corporate Broking)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Jessica Hodgson / Laura Thornton
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5701
Notes for Editors
About Synairgen
Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma, COPD and severe lung disease, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen's business strategy is the realisation of value via licensing transactions - validated in 2014 by the SNG001 agreement formed with AstraZeneca. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com
Follow the stocks
